Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

NCT00069758 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00069758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00069758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2003
Completion date
April 30, 2007
Enrollment
72
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma